Free Download

Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis

Volume: 0 - Issue: 0

First page: 0 - Last page: 0

S. Tsabouri - G. Ntritsos - F. Koskeridis - E. Evangelou - P. Olsson - K. Kostikas

Background: Allergic rhinitis (AR), an IgE mediated inflammatory disease, significantly impacts quality of life of a considerable proportion of the general population. Omalizumab, a humanized monoclonal antibody against IgE, has been evaluated for both seasonal and perennial AR. We aimed to assess the efficacy and safety of omalizumab in randomized controlled trials (RCTs) in inadequately controlled AR.
Methods: We conducted a systematic literature search of RCTs evaluating the safety and efficacy of omalizumab in AR. We synthesized evidence for clinical improvement of AR symptoms, quality of life, reduction of the use of rescue medication, and adverse events.
Results: The systematic search returned 289 articles, of which 12 RCTs were eligible for data extraction and meta-analysis. Omalizumab reduced the Daily Nasal Symptom Severity Score (DNSSS) by a summary standardized mean difference of -0.41 points with large heterogeneity; omalizumab significantly reduced the DNSSS both in the 3 cedar pollen-induced AR trials by -0.97 points and to a lower extent in the remaining five non-cedar trials by -0.19 points. Omalizumab also improved the Daily Ocular Symptom Severity Score (DOSSS) by a summary standardized mean difference of -0.30 points with large heterogeneity; the Rhino-conjunctivitis Quality of Life Questionnaire by a summary standardized mean difference of -0.45 points with no heterogeneity and the mean daily consumption of rescue antihistamines by a summary standardized mean difference of -0.21 with large heterogeneity. No statistically significant difference in the occurrence of adverse events was observed between omalizumab and placebo.
Conclusion: Our findings further support the efficacy and safety of omalizumab in the management of patients with allergic rhinitis inadequately controlled with a conventional treatment.

Rhinology 0-0: 0-0, 0000

To see the issue content and the abstract you do not have to login

Please login to download the full articles

If you do not have a subscription to Rhinology please consider taking one.

Click here to become a member of the European Rhinologic Society and a subscriber to the journal `RHINOLOGY`, from 2022. Subscription including membership fee: Euro 135.-

  1. Slot Online
  2. Situs Slot Online Terbaik Dan Terpercaya No 1
  3. Slot Gacor
  4. Daftar Situs Judi Slot Online
  5. Slot Terbaru:
  6. Slot Pragmatic Play
  7. Situs Slot Online Terpercaya
  8. Kumpulan Situs Judi Slot Terpercaya
  9. Game Slot Online
  10. Judi Slot Online Jackpot Terbesar
  11. Situs Judi Slot Online Terpercaya 2021
  12. Situs Slot Online Indonesia
  13. SLOT88
  14. 777 Slot Online
  15. Slot Joker123
  16. Situs Slot Online Terbaik
  17. Daftar Situs Slot Online
  18. Agen Slot Online Resmi
  19. Slot Deposit Pulsa
  20. Situs Slot Gacor
  21. Situs Judi Slot Online Terbaik & Judi Online 2021
  22. Agen Slot Online Terpercaya
  23. Daftar Situs Judi Slot Terbaik Dan Terpercaya No 1
  24. Link Alternatif Joker123
  25. Pragmatic Play Indonesia
  26. Daftar Situs Judi Slot Online Gampang Menang Terbaik 2021
  27. Raja Bet
  28. AloJudi Slot
  29. KayaMendadak88 Slot
  30. Situs Judi Slot Online:
  31. Situs slot gacor online terpercaya:
  32. Situs Judi Slot Online Joker Slot Gaming
  33. Judi Slot Online SLOT88
  34. Slot Online Gacor
  35. Judi Slot Pragmatic Play
  36. Link Alternatif: